An Internet-Based Education Program for Human Papillomavirus Vaccination Among Female College Students in Mainland China: Application of the Information-Motivation-Behavioral Skills Model in a Cluster Randomized Trial

Background Patients diagnosed with cervical cancer in the last 2 decades were mainly young females. Human papillomavirus (HPV) vaccination is the most radical way to prevent HPV infection and cervical cancer. However, most female college students in mainland China have not yet been vaccinated, and their relevant knowledge is limited. Theory-based education delivered via the internet is a potentially accessible and useful way to promote HPV vaccination among this population. Objective This 3-month follow-up study intended to identify the feasibility and efficacy of an information-motivation-behavioral skills (IMB) model–based online intervention for promoting awareness and willingness regarding HPV vaccination among female college students. Methods A 7-day online HPV education program for female college students in mainland China was developed using a cluster randomized trial design. Recruitment and questionnaire surveys were performed online without face-to-face contact. SPSS 23.0 was used for statistical analysis. The chi-square test and t test were used to compare differences in qualitative and continuous variables between intervention and control groups. The generalized estimating equation was used to test the effectiveness of the intervention with a consideration of the time factor. Results Among 3867 participants, 102 had been vaccinated against HPV before the study (vaccination rate of 2.6%). A total of 3484 participants were followed up after the baseline survey, with no statistical difference in the loss rate between the intervention and control groups during the intervention and follow-up periods. At different follow-up time points, HPV-related knowledge, and the motivation, behavioral skills, and willingness regarding HPV vaccination were higher in the intervention group than in the control group. HPV-related knowledge was statistically different between the 2 groups, while the motivation, behavioral skills, and willingness regarding HPV vaccination only showed statistical differences right after the intervention, reaching a peak right after the intervention and then gradually reducing over time. Furthermore, there was no statistical difference in the HPV vaccination rate between the 2 groups. Conclusions IMB model–based online education could be a promising way to increase the HPV vaccination rate and reduce the burden of HPV infection and cervical cancer among high-risk female college students in China. Trial Registration Chinese Clinical Trial Registry ChiCTR1900025476; http://www.chictr.org.cn/showprojen.aspx? proj=42672 International Registered Report Identifier (IRRID) RR2-DOI:10.1186/s12889-019-7903-x

Other: 1a-i) Identify the mode of delivery in the title Identify the mode of delivery.Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title.Avoid ambiguous terms like "online", "virtual", "interactive".Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g.email), use "computer-based" or "electronic" only if offline products are used.Use "virtual" only in the context of "virtual reality" (3-D worlds).Use "online" only in the context of "online support groups".Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.subitem not at all important essential

Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study subitem not at all important essential

Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any).Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study subitem not at all important essential

quotation marks "like this" to indicate direct quotes from your manuscript), or elab
rate on this item by providing additional information not in the ms, or briefly explain why the item is not appl

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...
ste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

2

of 37
24/07/2022 11:42 AM "Recruitment and questionnaire surveys were performed online without face-to-face contact." /07/2022 11:42 AM "Recruitment and questionnaire surveys were performed online without face-to-face contact."

"Recruitment and questionnaire surveys were performed online without face-to-face contact."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome -if the trial is negative (primary out "Recruitment and questionnaire surveys were performed online without face-to-face contact." 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome -if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons.CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...

me not changed), and the intervention was not used, discuss whether negat
ve results are attributable to lack of uptake and discuss reasons.CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

24/07/2022 11:42 AM "Among the 3867 participants, 102 had been vaccinated against HPV before the study at a vaccination rate of 2.64%.A total of 3484 participants were followe

of 37
24/07/2022 11:42 AM "Among the 3867 participants, 102 had been vaccinated against HPV before the study at a vaccination rate of 2.64%.A total of 3484 participants were followed up after the baseline survey, with no statistical difference in the loss rate between the two groups during the intervention and follow -up periods." up after the baseline survey, with no statistical difference in the loss rate between the two groups during the intervention and follow -up periods."

"Furthermore, there was no statistical difference "Furthermore, there was no statistical difference in the HPV vaccination rates between the two groups."

the H
V vaccination rates between the two groups."

information not in the ms, or briefly explain why the item is not applicable/relevant for your study 2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to information not in the ms, or briefly explain why the item is not applicable/relevant for your study 2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar subitem not at all important essential Does your paper address subitem 4a-ii?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4a-iii) Information giving during recruitment Information given during recruitment.Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.
iscuss the use of similar subitem not at all important essential Does your paper address subitem 4a-ii?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4a-iii) Information giving during recruitment Information given during recruitment.Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.
1 2 3 4 5
subitem not at all important essential


Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4b) Settings and locations where the data were collected Does your paper address CONSORT subitem 4b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direc subitem not at all important essential

Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4b) Settings and locations where the data were collected Does your paper address CONSORT subitem 4b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 10 of 37 24/07/2022 11:42 AM "The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college students were all self-isolated at home." quotes from your manuscript), or elabo

te on this item by providing additional
nformation not in the ms, or briefly explain why the item is not applicable/relevant for your study 10 of 37 24/07/2022 11:42 AM "The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college students were all self-isolated at home."

"The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college "Participating students were recruited through notices on campus or advertisements in social media groups, posted in advance by partner teachers.Interested participants scanned the Q "The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college "Participating students were recruited through notices on campus or advertisements in social media groups, posted in advance by partner teachers.Interested participants scanned the QR code on the notices or the advertisements to fill in their class name and provide the informed consent regarding the research objectives, requirements, procedures, benefits, and other study-related information." code on the notices or the advertisements to fill in their class name and provide the informed consent regarding the research objectives, requirements, procedures, benefits, and other study-related information."

students were all self-isolated at home." subitem not at all important essential


Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscri students were all self-isolated at home." subitem not at all important essential

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

(include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by provi
ing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owner

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript)."participants were given notebooks and pens with the logo of the research institution as incentives." [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript)."participants were given notebooks and pens with the logo of the research institution as incentives."


Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


5-ii) Describe the history/development process

Describe the history/development process of the application and previous

Does your paper address subitem 5-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

5-ii) Describe the history/development process
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.
formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/ se rates and help with interpreting results.
1 2 3 4 5
subitem not at all important essential


Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for yo subitem not at all important essential

Does your paper address subitem 5-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study r study


5-iii) Revisions and updating

Revisions and updating.Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe w

5-iii) Revisions and updating
Revisions and updating.Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial.Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).
ether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial.Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).
1 2 3 4 5
subitem not at all important essential


Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 12 of 37 24/07/2022 11:42 AM Not applicable.

"The intervention materials were developed by the research team based on the IMB model, uploaded and shared via the DingTalk platform by research assistants at each center."

Not applicable.


5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable. 1 2 subitem not at all important essential

Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 12 of 37 24/07/2022 11:42 AM Not applicable.
"The intervention materials were developed by the research team based on the IMB model, uploaded and shared via the DingTalk platform by research assistants at each center." Not applicable.

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable. 1 2 3 4 5

4 5

subitem not at all important essential
subitem not at all important essential Does your paper address subitem 5-iv?
Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Copy and paste relevant sections from the manuscript (include quotes in quo Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study ation marks "li e this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org,and/or publishing the source code or screenshots/videos alongside the article).As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.information not in the ms, or briefly explain why the item is not applicable/relevant for your study


5-vii)

5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org,and/or publishing the source code or screenshots/videos alongside the article).As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.information not in the ms, or briefly explain why the item is not applicable/relevant for your study

cess

Access: Describe how particip
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group.If known, describe how participants obtained "access to the platform and Internet" [1].To ensure access for editors/reviewers /readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study nts accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of pecific group.If known, describe how participants obtained "access to the platform and Internet" [1].To ensure access for editors/reviewers /readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
CONSORT-EHEALTH (V 1.

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number

5-x) Clarify the level of human involvement
Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered".It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 -generalizability).
nd expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered".It may be ne essary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 -generalizability).

1 2 3 4 5

subitem not at all important essential


Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Therefore, we developed two-day materials to popularize HPV knowledge, two-day materials on situational stories to motivate participants to vaccinate themselves against HP 1 2 3 4 5 subitem not at all important essential

Does your paper address subitem 5-x?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Therefore, we developed two-day materials to popularize HPV knowledge, two-day materials on situational stories to motivate participants to vaccinate themselves against HPV, and three-day materials on objective skills with self-decision making, self-efficacy, and objective conditions for making an appointment and receiving HPV vaccine."

and three-day materials on objective sk
lls with self-decision making, self-efficacy, and objective conditions for making an appointment and receiving HPV vaccine."

"It took about 10-15 minutes for the participants to read and learn the materials, depending on their learning ability."

Not applicable.

use the application, what triggered them, frequency etc.It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 -generalizability).CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 17 of 37 24/07/2022 11:42 AM "The primary outcome measures were self-reported willingness and uptake of HPV vaccination.At baseline and each follow-up, the p "It took about 10-15 minutes for the participants to read and learn the materials, depending on their learning ability." Not applicable.
use the application, what triggered them, frequency etc.It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 -generalizability).CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 17 of 37 24/07/2022 11:42 AM "The primary outcome measures were self-reported willingness and uptake of HPV vaccination.At baseline and each follow-up, the participants were asked 'Are you willing to get HPV vaccine in the future' and 'Have you been vaccinated against HPV' with 'Yes' and 'No' response options."

ticipa
ts were asked 'Are you willing to get HPV vaccine in the future' and 'Have you been vaccinated against HPV' with 'Yes' and 'No' response options."

"The secondary outcome measures were the information/knowledge, motivation, and behavioral skills towards H "The secondary outcome measures were the information/knowledge, motivation, and behavioral skills towards HPV vaccination, which was designed based on the IMB model." V vaccination, which was designed based on the IMB model."

"In the third month after the intervention, the participants were asked about their perceptions of barriers and facilitators in HPV vaccination, such as reasons for not receiving HPV vaccine, choices of HPV vaccine, opinions on promoting HPV vaccination in China, and willingness to uptake HPV vaccine under different scenarios."

"Among them, the information part consisted of eleven questions, such as 'HPV is related to the development of cervical cancer', the answers were 'Agree', 'Disagree' or 'Do not know' (Cronbach's alpha = 0.78) [29-32].Motivation for vaccination was measured by nineteen questions, such as 'Getting vaccinated for HPV will help protect me from HPV infection' (Cronbach's alpha = 0.71) [30, 33-35]; and behavioral skills as measured by ten questions, such as 'I feel confident in my ability to get vaccinated for HPV, even if it is expensive' (Cronbach's alpha = 0.88) [32,34], answers for these items were measured on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = neither disagree nor agree, 4 = agree, 5 = strongly agree).A description of baseline results for this study has been published [36]."

"During the daily intervention, we included quizzes on each day's topics to check and consolidate the knowledge gained by the participants." "In the third month after the intervention, the participants were asked about their perceptions of barriers and facilitators in HPV vaccination, such as reasons for not receiving HPV vaccine, choices of HPV vaccine, opinions on promoting HPV vaccination in China, and willingness to uptake HPV vaccine under different scenarios." "Among them, the information part consisted of eleven questions, such as 'HPV is related to the development of cervical cancer', the answers were 'Agree', 'Disagree' or 'Do not know' (Cronbach's alpha = 0.78) [29-32].Motivation for vaccination was measured by nineteen questions, such as 'Getting vaccinated for HPV will help protect me from HPV infection' (Cronbach's alpha = 0.71) [30, 33-35]; and behavioral skills as measured by ten questions, such as 'I feel confident in my ability to get vaccinated for HPV, even if it is expensive' (Cronbach's alpha = 0.88) [32,34], answers for these items were measured on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = neither disagree nor agree, 4 = agree, 5 = strongly agree).A description of baseline results for this study has been published [36]." "During the daily intervention, we included quizzes on each day's topics to check and consolidate the knowledge gained by the participants."

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manus
Copy and paste relevant sections from manuscript text ript text


6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/releva

6b) Any changes to trial outcomes after the trial commenced, with reasons
Does your paper address CONSORT subitem 6b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

for y
ur study 7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed


7a-i) Describe whether and how expected attr

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
tion was taken into account when calculating the sample size

Describe whether and how expected attrit Describe whether and how expected attrition was taken into account when calculating the sample size. 1 2 3 4 5 on was taken into account when calculating the sample size. 1 2 3 4 5

subitem not at all important essential


Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by provid subitem not at all important essential

Does your paper address subitem 7a-i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study NPT: When applicable, how care providers were allocated to each trial group Does your paper address CONSORT subitem 8a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "In order to facilitate the management of participants and reduce loss of follow-up, enrolled participants were randomly assigned by class to the intervention and the control groups.The investigator in each college who was blinded to the identity of the participants used computer software (the Excel program) to generate a series of random numbers for first-year Art and Science majored classes, respectively.Eligible participants would be identified as either the intervention group or the control group based on the class name they entered when they scanned the QR code on the recruiting information."

g additional information not in the ms, or brie
ly explain why the item is not applicable/relevant for your study NPT: When applicable, how care providers were allocated to each trial group Does your paper address CONSORT subitem 8a? * Copy and paste relevant sections fr uscript (include quotes in quotation ma

s "like this" to indicate direct quote
from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "In order to facilitate the management of participants and reduce loss of follow-up, enrolled participants were randomly assi

ed by class to the interventio
and the control groups.The investigator in each college who was blinded to the identity of the participants used computer software (the Excel program) to generate a series of random numbers for first-year Art and Science majored classes, respectively.Eligible participants would be identified as either the intervention group or the control group based on the class name they entered when they scanned the QR code on the recruiting information."


9) Mechanism used to implement t

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
allocation sequence (such as sequential

numbered containers), describing any s
eps taken to conceal the sequence until interventions were assigned


Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "In or

Does your paper address CONSORT subitem 10? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "In order to facilitate the management of participants and reduce loss of follow-up, enrolled participants were randomly assigned by class to the intervention and the control groups.Participants, data analysts, and investigators were all blinded to the randomized allocation, and only the research assistants in each center were able to see." 11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't.Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any). 1 2 3 4 5

r to f
cilitate the management of participa ts and reduce loss of follow-up, enrolled participants were randomly assigned by class to the intervention and the control groups.Participants, data analysts, and investigato s were all blind

to the randomized allocation, a
d only the research assistants in each center were able to see." 11a-i) Specify who was blinded, and who wasn't Specify who d, and who wasn't.Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any). 1 2 3 4 5

subitem not at all important essential Does your paper address subitem 11a-i?* Copy and paste relevan subitem not at all important essential Does your paper address subitem 11a-i?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator" Informed consent procedures (4a-ii) can create biases and certain expectations -discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".1 2 3 4 5

sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by prov
ding additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator" Informed consent procedures (4a reate biases and certain expectations -

scuss e.g., whether participants knew
which intervention was the "intervention of interest" and which one was the "comparator".1 2 3 4 5

subitem not at all important essential


Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct subitem not at all important essential

Does your paper address subitem 11a-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study As above, participants were not aware of the differences between the intervention and control groups.

uotes from your manuscript)
or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study As above, participants were not aware of the differences between the intervention and control groups.

information not in the ms, or briefly explain why the item is not applicable/relevant for your study 12a) Statistical methods used to compare groups for primary and information not in the ms, or briefly explain why the item is not applicable/relevant for your study 12a) Statistical methods used to compare groups for primary and secondary outcomes NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed outcomes NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or brie

Does your paper address CONSORT subitem 12a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

y expl
in why the item is not applicable/relevant for your study


12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missi

12a-i) Imputation techniques to deal with attrition / missing values
Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials.Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).
g values: Not al participants will use the intervention/comparator as intended and attrition is typically high in ehe

th trials.Spec
fy how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

1 2 3 4 5

subitem not at all important essential


Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes fr 1 2 3 4 5 subitem not at all important essential

Does your paper address subitem 12a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...
nuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

24/07/2022 11:42 AM "In order to increase the compliance of the control group and reduce the probability of breaking blindness, the control group was given seven days of information on COVID-19 prevention, which were organized and presented in the same format and platform as the educational materials in the intervention group."

See "statistical analysis" section.

"Analyses were conducted based on an intention-to-treat approach."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses Does your paper address CONSORT subitem 12b? * Copy and paste relevan

of 37
24/07/2022 11:42 AM "In order to increase the compliance of the control group and reduce the probability of breaking blindness, the control group was given seven days of information on COVID-19 prevention, which were organized and presented in the same format and platform as the educational materials in the intervention group." See "statistical analysis" section.
"Analyses were conducted based on an intention-to-treat approach." 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses Does your paper address CONSORT subitem 12b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or
laborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


X26) REB/I

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)
B Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval
1 2 3 4 5
subitem not at all important essential


Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like X26-i) Comment on ethics committee approval subitem not at all important essential

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

his" to indicate direct quotes
from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


x26-ii) Outline informed consent procedures

Outline informed consent pr

x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how?Checkbox, etc.?), and what information was provided (see 4a-ii).See [6] for some items to be included in informed consent documents.1 2 3 4 5 .g., if consent was obtained offline or online (how?Checkbox, etc.?), and what information was provided (see 4a-ii).See [6] for some items to be included in informed consent documents.1 2 3 4 5

subitem not at all important essential


Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" subitem not at all important essential

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...

indicate direct quotes from your manuscript
, or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

24/07/2022 11:42 AM "The effectiveness of the IMB model-based intervention on knowledge, motivation, behavioral skills, and willingness regarding HPV vaccination were examined using generalized estimating equations (GEE)."

Approved."This research was approved by the Institutional Review Board of Chinese Center for Diseas

of 37
24/07/2022 11:42 AM "The effectiveness of the IMB model-based intervention on knowledge, motivation, behavioral skills, and willingness regarding HPV vaccination were examined using generalized estimating equations (GEE)." Approved."This research was approved by the Institutional Review Board of Chinese Center for Disease Control and Prevention on October 24, 2019 (approval number: 201918-01)" X26-iii) Safety and security procedures Safety and security procedures, incl.privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) 1 2 3 4 5 and Prevention on October 24, 2019 (app

val number: 201918-01)" X26-iii) Safe
y and security procedures Safety and security procedures, incl.privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) 1 2 3 4 5

subitem not at all important essential


Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is n subitem not at all important essential

Does your paper address subitem X26-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

appli
able/relevant for your study


RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center


Do

RESULTS
13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *
s your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation mar Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM s "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM


Not applicable

"Interested participants scanned the QR code on the notices or the advertisements to fil

Not applicable
"Interested participants scanned the QR code on the notices or the advertisements to fill in their class name and provide the informed consent regarding the research objectives, requirements, procedures, benefits, and other study-related information.Potential participants were assessed for eligibility before the baseline survey." in their class name and provide the informed consent regarding the research objectives, requirements, procedures, benefi s, and other stu y-related information.Potential participants were assessed for eligibility before the baseline survey."

.

See Figure 1 The study flow chart.subitem not at all important essential


Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite .
See Figure 1 The study flow chart.subitem not at all important essential

Does your paper address subitem 13b-i?
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 14a) Dates defining the periods of recruitment and follow-up Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 14a) Dates defining the periods of recruitment and follow-up Does your paper address CONSORT subitem 14a? * Co

and paste relevant sections from the manuscript (include quot
s in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM

See Figure 1 The study flow chart.
Figure 1.
14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources a See Figure 1 The study flow chart.
14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources" 1 2 3 4 5 r "changes in computer hardware or Internet delivery resources" 1 2 3 4 5

subitem not at all important essential Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 14b) Why the trial ended or was stopped (early) Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, briefly explain why the item is not applicable/relevant for your study 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from y subitem not at all important essential Does your paper address subitem 14a-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 14b) Why the trial ended or was stopped (early) Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, briefly explain why the item is not applicable/relevant for your study 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) Does your paper address CONSORT subitem 17a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study ur manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical.This does not only refer to metrics of attriti In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical.This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length".These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).
n (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length".These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

CONSORT-EHEALTH (V 1.Both absolute and relative effect sizes were presented for binary outcomes.


18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1 2 3 4 5

subitem not at all important essential Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to in CONSORT-EHEALTH (V 1.Both absolute and relative effect sizes were presented for binary outcomes.

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).
1 2 3 4 5 subitem not at all important essential Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study In the Discussion part, "In addition, the results also indicated that this study was readily acceptable to the participants in both educational contents and forms, and which coincided with the feedback comments and suggestions from the participants at the end of the study (data are not presented in this manuscript)."Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...
icate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain wh the item is not applicable/relevant for your study In the Discussion part, "In addition, the results also indicated that this study was readily acceptable to the participants in both educational contents and forms, and which coincided with the feedback comments and suggestions from the participants at the end of the study (data are not presented in this manuscript)."Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

24/07/2022 11:42AM

"Future studies with randomization at the individual level, a longer follow-up period, and regular indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "This study investigated the effectiveness of an IMB model-based online education for HPV vaccination among female students from seven universities in mainland China.To our knowledge, this is the first study in China that evaluated the effect of an online health education guided by a health behavioral theory on improving the awareness, attitudes, and willingness towards HPV vaccination with randomized intervention and multiple follow-ups."

of 37
24/07/2022 11:42AM "Future studies with randomization at the individual level, a longer follow-up period, and regular indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "This study investigated the effectiveness of an IMB model-based online education for HPV vaccination among female students from seven universities in mainland China.To our knowledge, this is the first study in China that evaluated the effect of an online health education guided by a health behavioral theory on improving the awareness, attitudes, and willingness towards HPV vaccination with randomized intervention and multiple follow-ups." "Discussion_Principal findings" repetition of the ed "Discussion_Principal findings" repetition of the education will enable a better exploration of the effects of the intervention."Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...

ation will enable a better exploration of the effects of the intervention."Copy a
d paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...


of 37

24/07/2022 11:42AM

"Several study limitations must be considered.First, the effectiveness of the study might be compromised by the cluster randomization, and a mismatch in the number of participants between the intervention and control groups.In addition, although the IMB model-based intervention got relatively desirable results, the adve

of 37
24/07/2022 11:42AM "Several study limitations must be considered.First, the effectiveness of the study might be compromised by the cluster randomization, and a mismatch in the number of participants between the intervention and control groups.In addition, although the IMB model-based intervention got relatively desirable results, the adverse impacts of the COVID-19 pandemic could not be ignored, which included too much concern about getting COVID-19 infection, the possible trauma, and difficulties in making an appointment and getting vaccinated against HPV.Moreover, the participants were asked to self-report if they had received HPV vaccine before and within the study; however, the accuracy of these self-report data could not be verified through the community medical care system.Future studies with randomization at the individual level, a longer follow-up period, and regular repetition of the education will enable a better exploration of the effects of the intervention."

e impa
ts of the COVID-19 pandemic could not be ignored, which included too much concern about getting COVID-19 infection, the possible trauma, and difficulties in making an appointment and getting vaccinated against HPV.Moreover, the participants were asked to self-report if they had received HPV vaccine before and within the study; however, the accuracy of these self-report data could not be verified through the community medical care system.Future studies with randomization at the individual level, a longer follow-up period, and regular repetition of the education will enable a better exploration of the effects of the intervention."

Not applicable.

"The strengths of this study include the multicentered design, a representative and sufficient sample of the target population, and application of a health behavioral theory."



all important essentialDoes your paper address subitem 1a-i?*Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information n Not applicable.
"The strengths of this study include the multicentered design, a representative and sufficient sample of the target population, and application of a health behavioral theory." all important essentialDoes your paper address subitem 1a-i?*Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study1a-ii) Non-web-based components or important co-interventions in titleMention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support" t in the ms, or briefly explain why the item is not applicable/relevant for your study1a-ii) Non-web-based components or important co-interventions in titleMention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support"




1a-iii) Primary condition or target group in the title Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial 1 : Structured summary of trial design, methods, results, and conclusions NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.1b-i)Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT Mention key features/functionalities/components of the intervention and comparator in the abstract.If possible, also mention theories and principles used for designing the site.Keep in mind the needs of systematic reviewers and indexers by including imp 1a-iii) Primary condition or target group in the title Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial 1 : Structured summary of trial design, methods, results, and conclusions NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.1b-i)Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT Mention key features/functionalities/components of the intervention and comparator in the abstract.If possible, also mention theories and principles used for designing the site.Keep in mind the needs of systematic reviewers and indexers by including important synonyms.(Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it

tant s
nonyms.(No e: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it




(Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it) not at all important essential Does your paper address subitem 1b-ii?CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 4 of 37 24/07/2022 11:42 AM "College Females in Mainland China" "This 7-day online HPV education and 3 months' follow-up RCT study intended to identify the feasibility and efficacy of the Information-Motivation-Behavioral skills (IMB) mo (Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it) not at all important essential Does your paper address subitem 1b-ii?CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 4 of 37 24/07/2022 11:42 AM "College Females in Mainland China" "This 7-day online HPV education and 3 months' follow-up RCT study intended to identify the feasibility and efficacy of the Information-Motivation-Behavioral skills (IMB) model-based online intervention in promoting awareness, willingness, and vaccination against HPV among college females."

l-based online intervention in promoting awaren
ss, willingness, and vaccination against HPV among college females."




1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT Mention how participants were recruited (online vs. offline), e.g., from an open access website or from 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment).Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials).Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered.To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e.participants can self-enrol).(Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding itall important essential Does your paper address subitem 1b-iii?Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 1b-iv) RESULTS section in abstract must contain use data Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes.(Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it) clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment).Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials).Note: In traditional offline trials, an open trial (open-label trial) is a type of

linical trial in which both the researchers and participants know which treatment is being administered.To avoid confusion, use "blinded"
or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e.participants can self-enrol).(Note: Only report in the abstract what the main paper is reporting.If this informat

n is missing from the main body of text,
consider adding itall important essential Does your paper address subitem 1b-iii?Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information

ot in the ms, or briefly explain why the item is not applicable/r
levant for your study 1b-iv) RESULTS section in abstract must contain use data Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes.(Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it)




(Note: Only report in the abstract what the main paper is reporting.If this (Note: Only report in the abstract what the main paper is reporting.If this information is missing from the main body of text, consider adding it) all important essential Does your paper address subitem 1b-v?Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study INTRODUCTION 2a) In INTRODUCTION: Scientific background and explanation of rationale 2a-i) Problem and the type of system/solution Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program?Intended for a particular patient population?Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions?(Note: Details about the intervention are provided in "Methods" not at all important essential Does your paper address subitem 2a-i?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

format
on is missing from the main body of text, consider adding it) all important essential Does your paper address subitem 1b-v?Copy and paste relevant sections from the manuscript abstra t (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or e aborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study INTRODUCTION 2a) In INTRODUCTION: Scientific background and explanation of rationale 2a-i) Problem and the type of system/solution Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program?Intended for a particular patient population?Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions?(Note: Details about the intervention are provided in "Methods" not at all important essential Does your paper address subitem 2a-i?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional




4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.
4b-i) Report if outcomes were (self-)assessed through online questionnaires Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.all important essential Does your paper address subitem 4b-i?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Nota required item -describe only if this may bias results) ll importa t essential Does your paper address subitem 4b-i?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth med

me points including baseline, immediately after the intervention, 1 month, and 3 month
after the intervention."




5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used.Repli 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used.Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.all important essential Does your paper address subitem 5-v?

rting.all important essential Does your pape
subitem 5-v?




not at all important e not at all important essential Does your paper address subitem 5-vi?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...13 of 3724/07/2022 11:42 AM "Participants, data analysts, and investigators were all blinded to the randomized allocation, and only the research assistants in each center were able to see."Not applicable.

ential Does your paper address subitem
-vi?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewfor

hl=en_US&rm=full&fo...13 of 3724/07/2022 11:
2 AM "Participants, data analysts, and investigators were all blinded to the randomized allocation, and only the research assistants in each center were able to see."Not applicable.




all important essential Does your paper address subitem 5-vii?* Copy and past all important essential Does your paper address subitem 5-vii?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical frameworkDescribe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g.,[7, 8]  for terminology).This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6].This also includes a description of communication delivery channels and -if computermediated communication is a component -whether communication was synchronous or asynchronous[6].It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].all important essential Does your paper address subitem 5-viii?*

relevant sections from the manuscript (i
clude quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study5-viii) Mode of delivery, features/functionalities/compon

ts of the intervention and comparator, a
d the theoretical frameworkDescribe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional s rategy [1], behaviour change techniques

persuasive features, etc., see e.g.,[7, 8
for terminology).This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6].This also includes a description of c

municati
n delivery channels and -if computermediated communication is a component -whether communication was synchronous or asynchronous[6].It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].all important essential Does your paper address subitem 5-viii?*




all important essential Does your paper address subitem 5-xi?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 5-xii) Describe any co-interventi all important essential Does your paper address subitem 5-xi?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 5-xii) Describe any co-interventions (incl.training/support) Describe any co-interventions (incl.training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention.This includes training sessions and support [1].It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 -generalizability.all important essential Does your paper address subitem 5-xii?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed Does your paper address CONSORT subitem 6a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM Not applicable.Not co-interventions were included in our study.6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9all important essential Does your paper address subitem 6a-i?Copy and paste relevant sections from manuscript text 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.).Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.all important essential Does your paper address subitem 6a-ii?Copy and paste relevant sections from manuscript text 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).not at all important essential

s (inc
.training/support) Describe any co-interventions (incl.training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention.This includes training sessions and support [1].It may be necessary to distinguish between the level of training required or the trial, and the level of traini

for a routine application outside of a RCT setting (discuss under item 21 -generaliza
ility.all important essential Does your paper address subitem 5-xii?* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 6a) Completely defined pre-specified

imary and secondary outco
e measures, including how and when they were assessed Does your paper address CONSORT subitem 6a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elabo is item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 24/07/2022 11:42 AM Not applicable.Not co-interventions were included in our study.6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online qu

tionnaires, describe if they were validated for online use an
apply CHERRIES items to describe how the questionnaires were designed/deployed [9all important essential Does your paper address subitem 6a-i?Copy and paste relevant sections from manuscript text 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.).Use/adoption metrics are important process outcomes that should be reported in any ehealth tr

l.all important essential Does your paper address subitem 6a-ii?Copy and
paste relevant sections from manuscript text 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from part cipants was obtained (e.g., through emails, feedback forms, interviews, focus groups).not at all important essential


13b)

For each group, losses and exclusions after randomisation, together with reasons Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in ea

13b)
For each group, losses and exclusions after randomisation, together with reasons Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

group plotted over time, similar to a survival curve) or other figures or tables dem
nstrating usage/dose/engagement.




22-ii) Highlight unanswered new questions, suggest future researchHighlight unanswered new questions, suggest future research.all important essentialDoes your paper address subitem 22-ii?Copy and paste relevant sections f 22-ii) Highlight unanswered new questions, suggest future researchHighlight unanswered new questions, suggest future research.all important essentialDoes your paper address subitem 22-ii?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 20-i) Typical limitations in ehealth trialsTypical limitations in ehealth trials: Participants in ehealth trials are rarely blinded.Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error.Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

m the
anuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analys s 20-i) Typical limitations in ehealth trialsTypical limitations in ehealth trials: Participants in ehealth trials are rarely blinded.Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error.Discuss bi ses due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.


21)

Generalisability (external validity, applicability) of the trial findingsNPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the t

21)
Generalisability (external validity, applicability) of the trial findingsNPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial21-i) Generalizability to other populationsGeneralizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for not at all important essentialDoes your paper address subitem 21-i?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

al21-i) Generalizability to other populationsGeneralizability to
other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for not at all important essentialD aper address subitem 21-i?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 21-ii) Discuss if there were elements in the RCT that

setting (e.g., prompts/reminders, more human involvement, tra
ning sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.


In INTRODUCTION: Specific objectives or hypotheses Does your paper address CONSORT subitem 2b
"Cervical cancer, a serious infectious disease mostly caused by the high-risk types of humanpapilloma virus (HPV), is the fourth most common reason worldwide for tumor hospital admission inwomen.""Currently in China, there is a free HPV vaccination program launched in pilot regions among schoolgirls under 14 years old [24], but no effective strategies to improve HPV vaccine coverage amongfemale college students, who are at higher risk of HPV infection and suggested to be 'catch-up'population for HPV vaccination in many other countries."12345subitem not at all importantessentialmodel-based online intervention; second, to examine whether and

ow this intervention improved HPVvaccination; and
inally, to identify the barriers and facilitators of HPV vaccination among collegefemales in mainland China."
systems for other conditions/diagnoses, if appropiate), motivation for the systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings[2].Briefly justify the choice of the comparator.Does your paper address subitem 2a-ii?*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 2b) ?*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your studyMETHODSCONSORT-EHEALTH (V 1.6.1)-Submission/PublicationForm https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... 7 of 37 24/07/2022 11:42 AM "A review conducted in 2018 identified 70 scientific literatures providing supportive evidence that educations guided by health behavioral theories were effective in promoting HPV vaccination.""Thisstudy has three objectives: first, to evaluate the feasibility and acceptability of the IMB tudy, i.e.
what are the reasons for and what is th

context for this specific study, from w
ich stakeholder viewpoint is the study performed, potential impact of findings[2].Briefly justify the choice of the comparator.Does your paper address subitem 2a-ii?*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 2b) ?*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your studyMETHODSCONSORT-EHEALTH (V 1

.1)-Submission/PublicationForm https://docs.google.com/spreadsheet/viewform?hl=en_US
rm=full&fo... 7 of 37 24/07/2022 11:42 AM "A review conducted in 2018 identified 70 scientific literatures providing supportive evidence that educations guided by health behavioral theories were effective in promoting HPV vaccination.""Thisstudy has three objectives: first, to evaluate the feasibility and acceptability of the IMB


3a) Description of trial design (such as parallel, factorial) including allocation ratio 3b) Important changes to methods after trial commencement (such as Does your paper address C

3a) Description of trial design (such as parallel, factorial) including allocation ratio 3b) Important changes to methods after trial commencement (such as Does your paper address CONSORT subitem 3a? *
NSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" toi

icate
irect quotes from your manuscript), or elaborate on this item by providing additionalinformation not in the ms, or briefly explain why the item is not applicable/relevant for your study

eligibility criteria), with reasons Does your paper address CONSORT s

eligibility criteria), with reasons Does your paper address CONSORT subitem 3b? *
bitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" toindicate direct quotes from your manuscript), or elaborate on this item by providing additionalinformation not in the ms, or briefly explain why the item is not applicable/relevant for your study

3b-i) Bug fixes, Downtimes, Content Changes Bug

fixes, Downtimes, Content Changes: ehealth systems are often dynamic

3b-i) Bug fixes, Downtimes, Content Changes Bug
fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems.A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

stems.A description of changes to methods therefore also includes important changes made on the i
tervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].
12345subitem not at all importantessential

Does your paper address subitem 3b-i? Copy
CONSORT-EHEALTH

V 1.6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo..."Briefly, this study was a multicente
ed, 2-arm cluster randomized trial. First-year female collegestudents from seven universities in different geographic locations in mainland China were recruitedand randomly assigned 1:1 to either the IMB model-based intervention group or the waitlist controlgroup based on their class. "There were no important changes to our methods.8 of 3724/07

022 11:42 AM
and paste relevant sections from th
and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applic ble/relevant for your study


4a) Eligibility criteria for participants Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" toindicate direct quotes from your manuscript), or elaborate on this item by providing additionalinformation not in the ms, or briefly explain why the item is

4a-i) Computer / Internet literacy Computer
et literacy Computer
explicitlyclarified.12345subitem not at all importantessential
/ Internet literacy is often an implicit "de facto" eligibility criterion -this should be


Does your paper address subitem 4a-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by / Internet literacy is often an implicit "de facto" eligibility criterion -this should be

oviding additional information not in the ms, or br
efly explain why the item is not applicable/relevant for your study 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...There were no bug fixes, downtimes, or content changes to ou ehealth systems."The eligibility crite

a for the study included (1) female; (
) age ≥ 18 years; (3) first-year collegestudent; (4) without vaccination contraindications; (5) accessible to computers or smartphones."Not applicable.Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited(online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purelyweb-based trial, or there were face-to-face components (as part of the

ntervention or for assessment),i.e., to what degree got the study team to know the participan
. In online-only trials, clarify if participantswere quasi-anonymous and whether having multiple identities was possible or whether technical orlogistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.123459 of 3724/07/2022 11:42 AM

Does your paper address subitem 5-ix?

6.1) -Submission/

t/viewform?hl=en_US&rm=full&fo...
12345
ubitem not at all importantessential
14 of 3724/07/2022 11:42 AM "The forms, contents, and corresponding purposes of the IMB model-based education in this intervention are presented in Table1.""Theinterventionmaterialswere developed by the research team based on the IMB model, uploaded and shared vi 14 of 3724/07/2022 11:42 AM "The forms, contents, and corresponding purposes of the IMB model-based education in this intervention are presented in Table1.""Theinterventionmaterialswere developed by the research team based on the IMB model, uploaded and shared via the DingTalk platform by research assistants at each center.Upon randomization, the intervention group access the materials by scanning the Quick Response (QR) code on each of the cover pages of educational materials."5-ix)Describeuse parametersDescribe use parameters (e.g., intended "doses" and optimal timing for use).Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

platform by research assistants at each center.Upon randomization, the intervention group access the materials by
canning the Quick Response (QR) code on each of the cover pages of educational materials."5-ix)Describeuse parametersDescribe use parameters (e.g., intended "do

s" and optimal timing for use).Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, he
viness of use, if any, or was the intervention used ad libitum.




EHEALTH (V 1.6.1)-Submission/PublicationFormhttps://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...The intervention materials were developed by the research team based on the IMB model, uploaded and shared via the DingTalk platform by research assistants at each center.Upon randomization, the intervention group access the materials by scanning the Quick Response (QR) c EHEALTH (V 1.6.1)-Submission/PublicationFormhttps://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...The intervention materials were developed by the research team based on the IMB model, uploaded and shared via the DingTalk platform by research assistants at each center.Upon randomization, the intervention group access the materials by scanning the Quick Response (QR) code on each of the cover pages of educational materials.""Theforms,contents, and corresponding purposes of the IMB model-based education in this intervention are presented in Table1."

e on each of the cover pages of educational materials.""Theforms,co
tents, and corresponding purposes of the IMB model-based educ his intervention are presented in Table

"
"15 of 3724/07/2022 11:42 AM
5-xi) Re
5-xi) Report any prompts/reminders usedReport any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to CONSORT- ort any prompts/reminders usedReport any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to CONSORT-


7b) When applicable, explanation of any interim analyses and stopping guidelines Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sec

7b) When applicable, explanation of any interim analyses and stopping guidelines Does your paper address CONSORT subitem 7b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for study

or elaborate on this item by providing addi
ional information not in the ms, or briefly explain why the item is not applicable/relevant for study


8a) Method used to generate the random allocation sequence 8b) Type of randomisation; details of any restriction (such as blocking and block size) Does

Details of the sample size calculation were described in

8a) Method used to generate the random allocation sequence 8b) Type of randomisation; details of any restriction (such as blocking and block size) Does
Details of the sample size calculation were described in the publised protocol.(SiM, Su X, Jiang Y, Qiao Y, Liu Y. Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial.BMC Public Health.2019; 19:1546 ed protocol.(SiM, Su X, Jiang Y, Qiao Y, Liu Y. Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial.BMC Public Health.2019; 19:1546
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo.... doi:10.1186/s12889-019-7903-x)Not applicable.19 of 3724/07/2022 11:42 AM
your paper address CONSORT subitem 8b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to


Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 11a) If done, who was blinded after assignment to interventions (for example, p your paper address CONSORT subitem 8b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
rticipants, care providers, thos assessing outcomes) and how
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Formhttps://docs.go

11b) If relevant, description of the similarity of interventions
data analysts, and investigators were all blinded to the randomized allocation, and only the research assistants in each center were able to see."

llocation, and only the research assistants
n each center were able to see."
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo..."Participants,21 of 3724/07/2022 11:42 AM
(this item is usually not relevant for ehealth trials (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)Does your paper address CONSORT subitem 11b? *Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional as it refers to similarity of a placebo

r sham intervention to a active medica
ion/intervention)Does your paper address CONSORT subitem 11b? *Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional


Does your paper address CONSORT subi

m 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like th
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study s" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


15) A table showing baseline demographic and clinical characteristics for each group

The flow chart for participant recruitment is presented in Figure1.From February 2020 t

15) A table showing baseline demographic and clinical characteristics for each group
The flow chart for participant recruitment is presented in Figure1.From February 2020 to March 2020, a total of 4051 female college students were recruited and screened, among whom 83 refused to participate in the study, 101 did not meet the inclusion criteria, and 102 reported that they had been vaccinated with HPV vaccine prior to the study.""The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college students were all self-isolated at home." Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

March 2020, a total of 4051 female coll
ge students were recruited and screened, among whom 83 refused to participate in the study, 101 did not meet the inclusion criteria, and 102 reported that they had been vaccinated with HPV vaccine prior to the study.""The whole process of participant recruitment, data collection, and intervention was conducted online , which was timed to coincide with the outbreak of COVID-19 in China, when Chinese college students were

ll sel
-isolated at home." Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Formhttps://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...Does your paper address CONSORT subitem 15? *"Not applicable.NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) andcenters (volume) in each group26 of 3724/07/2022 11:42 AM

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.
12345subitem not at all importa

15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known. tessential

Does

Does your paper address subitem 15-i? *
your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manus Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n this item by providing additional information not
in the ms, or briefly explain why the item is not applicable/relevant for your study


16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group).Always clearly define "use" of the intervention.
12345subitem not at all importantessential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applic

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 16-i) Report multiple "denominators" and provide definitions
Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group).Always clearly define "use" of the intervention.

Does your paper address subitem 16-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...

ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

that this is no longer a randomized sample (see 18-i).
12345subitem not at all
importantessential

Does your paper address subitem 16-ii?


Does your paper address subitem 17a-i?

6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... Sample sizes included as "n(%)" throughout results, Table2, Table4, and Table6.We have used intention-to-treat analysis and identified the group (intervention group or control group) of participants based on the ID number entered.Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in

Does your paper address subitem 17a-i?
6.1) -Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo... Sample sizes included as "n(%)" throughout results, Table2, Table4, and Table6.We have used intention-to-treat analysis and identified the group (intervention group or control group) of participants based on the ID number entered.Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

e ms, or briefly explain why the ite
is not applicable/relevant for your study
12345subitem not at all importantessentialStandard deviations and alpha levels are reported.28 of 3724/07/2022 11:42 AM

17b) For binary outcomes, presentation o

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Does your paper address CONSORT subitem 17b? *
both absolute and relative effect sizes is recommended Does your paper address CONSORT subitem 17b? *

Copy and paste rele Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

nt sec
ions from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not appli

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory Does your paper address CONSORT subitem 18? *
erformed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory Does your paper address CONSORT subitem 1

*

Copy and paste relevant sections from the manus
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...

ipt (include quotes in quotation marks "like this" t
indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.co /spreadsheet/viewform?hl=en_US&rm=full&fo...
Not applicable.29 of 3724/07/2022 11:42 AM

19) All important harms or unintend

d effects i
(for specific guidance see CONSORT for harms)Does your paper address CONSORT subitem 19? *Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study19-i) Include privacy breaches, technical problemsInclude privacy breaches, technical problems.This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents."Unintendedeffects"also includes unintended positiveDoes your paper address subitem 19-i?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses.This includes (if available) reasons for why people did or did not use the application as intended by the developers.
Does your paper address subitem 19-ii?Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your

study DISCUSSION 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group NPT:

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).CONSORT-EHEALTH (V 1.6.1)-Submission/Publication Form https://docs.google.com/spreadsheet/viewform?hl=en_US&rm=full&fo...
subitem not at all important essential Does your paper address subitem 22-i?*Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to 31 of 37 24/07/2022 11:42 AM Not applicable.